Pharma Journalist -

PhaseBio Pharmaceuticals announced that it has completed dosing in the first cohort of subjects in its Phase 1 clinical trial of PB2452 (formerly MEDI2452), a reversal agent for the…
Read More...

MyoKardia, Inc. announced that the first patient has been dosed in the company’s Phase 2 MAVERICK-HCM clinical trial. MAVERICK-HCM is the first clinical trial of mavacamten in…
Read More...

Agilent Technologies Inc. and Lasergen, Inc. (Lasergen) announced that they have signed a definitive agreement for Agilent to acquire the remaining shares of Lasergen, an emerging…
Read More...

Ferring Pharmaceuticals and Rebiotix Inc. announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies…
Read More...

Ubiquigent Limited announced that it has entered into a multi-year strategic R&D collaboration agreement with FORMA Therapeutics for the design and development of novel…
Read More...

Cardiva Medical announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE Vascular Closure System.…
Read More...

Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine announced that it has signed a merger agreement with…
Read More...

Boehringer Ingelheim and OSE Immunotherapeutics announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist…
Read More...

Aradigm Corporation announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for Linhaliq for the treatment of…
Read More...

SMi Reports:The National Institutes of Health announce one of the most ambitiousmedical projects in biobanking, which will commence this spring. In the run up to SMi’s 8thAnnual…
Read More...